---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007732"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:01:31.769866+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma reports 2022 net loss $21M, cash $28.8M; LNC platform updates

## Summary
- Revenue $3.2M from BioNTech collaboration, vs $33K in 2021.
- Net loss $21.0M ($0.10/share) vs $23.7M ($0.11/share) in 2021.
- Cash and marketable securities $28.8M at Dec 31, 2022, sufficient into Q2 2024.
- Anticipates Q2 2023 in vivo data from BioNTech and National Resilience collaborations.
- Planned FDA meeting for MAT2203 Phase 3; potential BARDA/NIH funding.

## SEC filing metadata
- accession: 0001493152-23-007732
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223007732/0001493152-23-007732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223007732/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007732
- JSON: https://secwatch.observer/filing/0001493152-23-007732.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007732.txt

## Key facts
- Earnings Releases
  Matinas BioPharma Holdings, Inc. reported the year ended December 31, 2022 results: revenue $3.2 million, net income $21.0 million, EPS $0.10 per share.
  - Period: the year ended December 31, 2022
  - Revenue: $3.2 million
  - Net income: $21.0 million
  - EPS: $0.10 per share
  - Result: reported results
  source text: Revenue for the year ended December 31, 2022 was $3.2 million, which was generated from the research collaboration with BioNTech SE. This compares with revenue for the year ended December 31, 2021 of $33,000, which was generated from the feasibility study agreement with Genentech Inc. Total costs and expenses for 2022 were $27.8 million compared with $24.8 million for 2021. The increase was due primarily to higher research and development expenses reflecting the later stage of the Company’s clinical development programs. Income from selling unused New Jersey net operating losses (NOLs) and research and development tax credits was $3.5 million and $1.3 million for 2022 and 2021, respectively. The net loss attributable to common shareholders for 2022 was $21.0 million, or $0.10 per share, compared with a net loss attributable to common shareholders for 2021 of $23.7 million, or $0.11 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315223007732/0001493152-23-007732-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.